Monday, Jan 29, 1990
New York -- January 29, 1990 --In a national survey, more than eight out of ten polled physicians selected Activase (Alteplase, recombinant), a tissue plasminogen activator or t-PA, as the therapy they would choose if they themselves were having a heart attack.
Overall, 84 percent of the physicians said they would choose Activase when asked, "If you were brought into a hospital emergency room suffering an acute myocardial infarction (heart attack) and were eligible for thrombolysis (clot-dissolving therapy), with which intravenous thrombolytic agent would you want to be treated?" The commercially available agents at the time of the survey were Activase, streptokinase and urokinase.
The telephone survey, conducted from October 10 to 19, 1989 by Yankelovich Clancy Shulman, polled 500 cardiologists and emergency medicine practitioners. Ninety-one percent of those surveyed are affiliated with hospitals with over 100 beds; 84 percent have been in practice more than five years.
Thrombolytic or clot-dissolving agents are used on an emergency basis to treat heart attacks. These drugs dissolve clots in coronary arteries, the cause of most heart attacks.
Activase, a product of recombinant DNA technology, was licensed in November 1987 and is marketed by Genentech. Activase is used in heart attacktreatment to dissolve the blood clot and restore normal blood flow to the heart. Activase has been shown to reduce deaths (when administered within five hours of symptom onset), improve heart function and reduce the incidence of congestive heart failure following an attack.
The survey was sponsored by Genentech, Inc., a biotechnology company focusing on the development, manufacture and marketing of pharmaceutical products produced by recombinant DNA technology.
# # #